Prescient Therapeutics Management
Management criteria checks 3/4
Prescient Therapeutics' CEO is Steven Yatomi-Clarke, appointed in Feb 2016, has a tenure of 8.75 years. total yearly compensation is A$657.01K, comprised of 63% salary and 37% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth A$414.21K. The average tenure of the management team and the board of directors is 9.2 years and 9.5 years respectively.
Key information
Steven Yatomi-Clarke
Chief executive officer
AU$657.0k
Total compensation
| CEO salary percentage | 63.0% |
| CEO tenure | 8.8yrs |
| CEO ownership | 1.4% |
| Management average tenure | 9.2yrs |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$657k | AU$414k | -AU$8m |
| Mar 31 2024 | n/a | n/a | -AU$8m |
| Dec 31 2023 | n/a | n/a | -AU$8m |
| Sep 30 2023 | n/a | n/a | -AU$7m |
| Jun 30 2023 | AU$663k | AU$400k | -AU$7m |
| Mar 31 2023 | n/a | n/a | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$5m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | AU$771k | AU$392k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$5m |
| Sep 30 2021 | n/a | n/a | -AU$5m |
| Jun 30 2021 | AU$800k | AU$360k | -AU$4m |
| Mar 31 2021 | n/a | n/a | -AU$4m |
| Dec 31 2020 | n/a | n/a | -AU$3m |
| Sep 30 2020 | n/a | n/a | -AU$3m |
| Jun 30 2020 | AU$639k | AU$392k | -AU$3m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$4m |
| Sep 30 2019 | n/a | n/a | -AU$4m |
| Jun 30 2019 | AU$586k | AU$367k | -AU$4m |
| Mar 31 2019 | n/a | n/a | -AU$3m |
| Dec 31 2018 | n/a | n/a | -AU$3m |
| Sep 30 2018 | n/a | n/a | -AU$3m |
| Jun 30 2018 | AU$479k | AU$330k | -AU$3m |
Compensation vs Market: Steven's total compensation ($USD426.96K) is above average for companies of similar size in the Australian market ($USD297.98K).
Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.
CEO
Steven Yatomi-Clarke
8.8yrs
Tenure
AU$657,007
Compensation
Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 8.8yrs | AU$657.01k | 1.39% A$ 414.2k | |
| CFO & Company Secretary | 9.8yrs | AU$158.40k | no data | |
| Director of Clinical Affairs & Operations | less than a year | no data | no data | |
| Chief Medical Officer | 9.6yrs | AU$157.36k | no data |
9.2yrs
Average Tenure
Experienced Management: PTX's management team is seasoned and experienced (9.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 10yrs | AU$657.01k | 1.39% A$ 414.2k | |
| Independent Non-Executive Chairman | 10.4yrs | AU$97.96k | 0.027% A$ 8.1k | |
| Independent Non-Executive Director | 10yrs | AU$61.41k | 0.049% A$ 14.7k | |
| Chairman of Clinical Advisory Board | 13.4yrs | no data | no data | |
| Member of Clinical Advisory Board | 13.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 10.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 9yrs | no data | no data | |
| Member of Scientific Advisory Board | 9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Non-Executive Director | 4.4yrs | AU$61.41k | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data |
9.5yrs
Average Tenure
Experienced Board: PTX's board of directors are considered experienced (9.5 years average tenure).